Resultados globales: 10 registros encontrados en 0.01 segundos.
Artículos, Encontrados 10 registros
Artículos Encontrados 10 registros  
1.
20 p, 4.1 MB High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer / Palafox, Marta (Hospital Universitari Vall d'Hebron) ; Monserrat, Laia (Hospital Universitari Vall d'Hebron) ; Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ; Villacampa Javierre, Guillermo (Hospital Universitari Vall d'Hebron) ; Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ; Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ; Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ibrahimi, Nusaibah (University Paris-Saclay) ; Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ; Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ; Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ; Òdena, Andreu (Hospital Universitari Vall d'Hebron) ; Sánchez-Guixé, Mònica (Hospital Universitari Vall d'Hebron) ; Capelán, Marta (Hospital Universitari Vall d'Hebron) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Bruna, Alejandra (The Institute of Cancer Research (Londres)) ; Rodríguez, Olga (Hospital Universitari Vall d'Hebron) ; Guzmán, Marta (Hospital Universitari Vall d'Hebron) ; Grueso, Judit (Hospital Universitari Vall d'Hebron) ; Viaplana, Cristina (Hospital Universitari Vall d'Hebron) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ; Su, Faye (Novartis Pharmaceuticals) ; Lin, Kui (Genentech, Inc., South San Francisco) ; Clarke, Robert B. (Manchester Breast Centre) ; Caldas, Carlos (Cancer Research UK) ; Arribas, Joaquín V (Hospital Universitari Vall d'Hebron) ; Michiels, Stefan (University Paris-Saclay) ; García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ; Turner, Nicholas C. (The Breast Cancer Now Research Centre) ; Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Dienstmann, Rodrigo (Hospital Universitari Vall d'Hebron) ; Verma, Chandra S. (National University of Singapore) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ; Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ; Arnedos, Monica (Inserm Unit U981 (França)) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. [...]
2022 - 10.1038/s41467-022-32828-6
Nature communications, Vol. 13 (september 2022)  
2.
1 p, 526.7 KB Author Correction : High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer / Palafox, Marta (Vall d'Hebron Institut d'Oncologia) ; Monserrat, Laia (Vall d'Hebron Institut d'Oncologia) ; Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ; Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ; Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ; Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ibrahimi, Nusaibah (University Paris-Saclay. Oncostat U1018, Inserm) ; Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ; Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ; Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ; Òdena, Andreu (Vall d'Hebron Institut d'Oncologia) ; Sánchez-Guixé, Mònica (Vall d'Hebron Institut d'Oncologia) ; Capelán, Marta (Hospital Universitari Vall d'Hebron) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Bruna, Alejandra (The Institute of Cancer Research. Preclinical Modelling of Pediatric Cancer Evolution Group) ; Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ; Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Su, Faye (Novartis Pharmaceuticals) ; Lin, Kui (Genentech, Inc., South San Francisco) ; Clarke, Robert B. (Manchester Breast Centre) ; Caldas, Carlos (Cancer Research UK) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Michiels, Stefan (University Paris-Saclay) ; García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ; Turner, Nicholas C. (The Breast Cancer Now Research Centre) ; Prat, Aleix (IOB Institute of Oncology (Barcelona, Catalunya)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Verma, Chandra S. (National University of Singapore. Department of Biological Sciences) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ; Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center. Departments of Pathology and Human Oncology and Pathogenesis Program) ; Arnedos, Monica (Inserm Unit U981) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
2022 - 10.1038/s41467-022-34580-3
Nature communications, Vol. 13 (november 2022)  
3.
3 p, 240.8 KB PCIG : a web-based application to explore immune-genomics interactions across cancer types / Pedrola, Anna (Vall d'Hebron Institut d'Oncologia) ; Franch-Expósito, Sebastià (Memorial Sloan Kettering Cancer Center) ; Lahoz, Sara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteban-Fabró, Roger (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Bassaganyas, Laia (University of Cambridge. Department of Medical Genetics) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Genomic alterations can modulate the tumor immunophenotype depending on their nature and tissue of origin. Although this immune-genomic interaction may shape disease progression and response to immunotherapy, the factors governing such dynamics and the influence of each tissue-specific context remain poorly understood. [...]
2022 - 10.1093/bioinformatics/btac111
Bioinformatics, Vol. 38, Issue 8 (March 2022) , p. 2374-2376  
4.
12 p, 1.2 MB Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy / Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Sánchez Martínez, M. Olga (Vall d'Hebron Institut d'Oncologia) ; Martínez, Sandra (Vall d'Hebron Institut d'Oncologia) ; Domínguez Luengo, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Ruíz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Céspedes, Maria Concepció (Hospital Universitari Vall d'Hebron) ; Peñuelas, Ángeles (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Llurba, E.. (Institut d'Investigació Biomèdica Sant Pau) ; Córdoba, Octavi (Institut d'Investigació Sanitària Illes Balears) ; Universitat Autònoma de Barcelona
Anthracyclines and taxanes are being used as a standard treatment for breast cancer diagnosed during pregnancy. These chemotherapy regimens allow the continuation of pregnancy without delaying cancer treatment with relatively good maternal and neonatal outcomes. [...]
2021 - 10.3390/cancers13040923
Cancers, Vol. 13 (february 2021)  
5.
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
6.
8 p, 2.4 MB Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations / Tamborero, David (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rubio-Perez, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ; Deu-Pons, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Schroeder, Michael P. (Charité - Universitätsmedizin Berlin) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Rovira, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ; Tusquets, Ignasi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Albanell Mestres, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; De Torres, Carmen (Institut de Recerca Sant Joan de Déu) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. [...]
2018 - 10.1186/s13073-018-0531-8
Genome Medicine, Vol. 10 (March 2018) , art. 25  
7.
8 p, 357.7 KB Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer / Grasselli, Julieta (Institut Català d'Oncologia) ; Elez, Elena (Universitat Autònoma de Barcelona) ; Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ; Matito, Judit (Vall d'Hebron Institut d'Oncologia) ; Santos Vivas, Cristina (Institut Català d'Oncologia) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Vidal, J. (Hospital del Mar (Barcelona, Catalunya)) ; Garcia, M.. (Institut Català d'Oncologia) ; Viéitez, J. M. (Hospital Universitario Central de Asturias) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Falcó, E. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Lopez Lopez, C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Aranda, E. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Jones, F. (Sysmex Inostics, Mundelein, USA) ; Sikri, V (Sysmex Inostics, Mundelein, USA) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Montagut, Clara (Hospital del Mar (Barcelona, Catalunya)) ; Azuara, D. (Institut Català d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Salazar, R. (Institut Català d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301  
8.
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Elez, Elena (Hospital Universitari Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autònoma de Barcelona) ; Palmer, Héctor G (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
9.
9 p, 435.9 KB Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study / Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ; Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ; Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ; Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ; Buchanan, Daniel D (The University of Melbourne) ; Clendenning, M. (The University of Melbourne) ; Rosty, C. (The University of Melbourne) ; Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ; Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ; Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ; Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Sargent, D. (Mayo Clinic, Rochester, USA) ; Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031  
10.
33 p, 1.9 MB The Consensus Molecular Subtypes of Colorectal Cancer / Guinney, Justin (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Wang, Xin (City University of Hong Kong. Department of Biomedical Sciences (China)) ; de Reyniès, Aurélien (Ligue Nationale Contre le Cancer (France)) ; Schlicker, Andreas (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Soneson, Charlotte (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Marisa, Laetitia (Ligue Nationale Contre le Cancer (France)) ; Roepman, Paul (Agendia NV (Netherlands)) ; Nyamundanda, Gift (The Institute of Cancer Research (UK)) ; Angelino, Paolo (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Bot, Brian M. (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Morris, Jeffrey S. (The University of Texas M.D. Anderson Cancer Center (USA)) ; Simon, Iris M. (Agendia NV (Netherlands)) ; Gerster, Sarah (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Fessler, Evelyn (University of Amsterdam (Netherlands)) ; de Sousa e Melo, Felipe (University of Amsterdam (Netherlands)) ; Missiaglia, Edoardo (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Ramay, Hena (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Barras, David (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Homicsko, Krisztian (Ecole Polytechnique Federale de Lausanne (Switzerland)) ; Maru, Dipen (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Manyam, Ganiraju C. (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Broom, Bradley (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Boige, Valerie (Gustave Roussy, Villejuif (France)) ; Perez-Villamil, Beatriz (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ; Laderas, Ted (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Salazar, Ramon (Institut d'Investigació Biomèdica de Bellvitge) ; Gray, Joe W. (Oregon Health Sciences University (USA)) ; Hanahan, Douglas (Ecole Polytechnique Federale de Lausanne (Switzerland)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Bernards, Rene (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Friend, Stephen H. (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Laurent-Puig, Pierre (Universite Paris Descartes (France)) ; Medema, Jan Paul (LEXOR, Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam (Netherlands)) ; Sadanandam, Anguraj (The Institute of Cancer Research (UK)) ; Wessels, Lodewyk (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Delorenzi, Mauro (University of Lausanne (Switzerland)) ; Kopetz, Scott (The University of Texas M.D. Anderson Cancer Center (USA)) ; Vermeulen, Louis (LEXOR, Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam (Netherlands)) ; Tejpar, Sabine (Universitair ziekenhuis Leuven (Belgium)) ; Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. [...]
2015 - 10.1038/nm.3967
Nature Medicine, Vol. 21, Num. 11 (November 2015) , p. 1350-1356  

Vea también: autores con nombres similares
1 Dienstmann, R
1 Dienstmann, Rodrigo.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.